Drugs / Danvatirsen
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05986240 | May 2024 → Jun 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03819465 | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03527147 | Jun 2018 → Mar 2021 | diffuse large B-cell lymphoma | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT03421353 | Feb 2018 → Jan 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03394144 | Jan 2018 → Apr 2019 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02546661 | Dec 2016 → Mar 2020 overdue | infiltrating bladder urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02549651 | Jul 2016 → Feb 2019 | diffuse large B-cell lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01839604 | May 2013 → Feb 2015 | adult hepatocellular carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05814666 | May 2023 → Aug 2025 | head and neck squamous cell carcinoma | Flamingo Therapeutics NV | Terminated | No outcome recorded |
| Phase 2 | NCT03794544 | Mar 2019 → Jan 2021 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03334617 | Dec 2017 → Sep 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02983578 | Mar 2017 → Aug 2025 overdue | colorectal carcinoma, non-small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02417753 | Apr 2015 → Apr 2016 | digestive system cancer, ovarian cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | danvatirsen | “antisense oligonucleotide targeting STAT3 (danvatirsen)” PMID 36270753 ↗ Oct 2022 |
| Known as | AZD9150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02546661 ↗ |
| Known as | ISIS-481464 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297739 ↗ |
| Known as | ISIS-STAT3Rx | “A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma” NCT01839604 ↗ |
| Action | Inhibit | “target and down-regulate expression of human STAT3 mRNA” NCT02417753 ↗ |
| Modality | Antisense oligonucleotide | “AZD9150 is an antisense oligonucleotide designed to target and down-regulate expression of human STAT3 mRNA.” NCT02417753 ↗ |
| Route | Intravenous | “Intravenous infusion over 3 hours.” NCT01839604 ↗ |
| Target | STAT3 | “target and down-regulate expression of human STAT3 mRNA” NCT02417753 ↗ |